{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALK-positive+Advanced+Tumors&page=2", "query": { "condition": "ALK-positive Advanced Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ALK-positive+Advanced+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T19:04:06.853Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03868423", "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "ALK Fusion Protein Expression", "ALK Gene Amplification", "ALK Gene Mutation", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Central Nervous System", "Metastatic Malignant Solid Neoplasm", "ROS1 Fusion Positive", "ROS1 Gene Amplification", "ROS1 Gene Mutation" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sameek Roychowdhury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03-20", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03868423" }, { "nct_id": "NCT01828112", "title": "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 231, "start_date": "2013-06-28", "completion_date": "2023-11-10", "has_results": true, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 13, "location_summary": "Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Marywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01828112" }, { "nct_id": "NCT02737501", "title": "ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer", "Advanced Malignancies", "Carcinoma" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ariad Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2016-05-26", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2021-08-20", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 12, "location_summary": "Sedona, Arizona • Bellflower, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02737501" }, { "nct_id": "NCT07567352", "title": "A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small-Cell Lung", "ALK-positive Advanced NSCLC", "ALK-positive Non-small-cell Lung Cancer", "ALK-positive NSCLC" ], "interventions": [ { "name": "lorlatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-05-01", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07567352" }, { "nct_id": "NCT02521051", "title": "Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-09-28", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02521051" }, { "nct_id": "NCT03178071", "title": "Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non Small Cell Lung Cancer ALK Positive or ROS1 Positive" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 49, "location_summary": "Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03178071" }, { "nct_id": "NCT01752400", "title": "AUY922 for Advanced ALK-positive NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AUY922", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-01", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752400" }, { "nct_id": "NCT01284192", "title": "Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies", "Positive for Anaplastic Lymphoma Kinase", "Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS", "Solid Tumor", "B-Cell Lymphoma" ], "interventions": [ { "name": "ASP3026", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2010-12", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-06-28", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 6, "location_summary": "Orange, California • Sacramento, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01284192" }, { "nct_id": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "Gefitinib", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 247, "start_date": "2019-06-25", "completion_date": "2025-05-06", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944772" }, { "nct_id": "NCT07140016", "title": "A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Anaplastic Lymphoma Kinase (ALK) Positive" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-09-22", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-07-23T19:04:06.853Z", "location_count": 9, "location_summary": "Fullerton, California • Orange, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140016" } ] }